Logo
x

Search

Subscribe Now

Blueprint Medicine

Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosi...

  • May 23, 2023
PharmaShots Weekly Snapshots (May 22 - 26, 2023)

    PharmaShots Weekly Snapshots (May 22 - 26, 2023)

    • May 26, 2023
    Blueprint Medicines Published (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Indolent Systemic Mastocytosis in the NEJM

      Blueprint Medicines Published (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Indolent Systemic Mastocytosis...

      • May 24, 2023
      Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosis

        Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosi...

        • May 23, 2023
        PharmaShots Weekly Snapshots (February 27 – March 03, 2023)

          PharmaShots Weekly Snapshots (February 27 – March 03, 2023)

          • March 3, 2023
          Blueprint Medicines Presents P-II Trial (PIONEER) of Ayvakit (avapritinib) for Indolent Systemic Mastocytosis at AAAAI 2023

            Blueprint Medicines Presents P-II Trial (PIONEER) of Ayvakit (avapritinib) for Indolent Systemic Mastocytosis at AAAAI 2023

            • February 27, 2023
            Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

              Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients...

              • February 13, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.